Alpha Tau Medical

What Alpha Tau Medical does

Alpha Tau Medical Ltd. is a clinical-stage Israeli oncology therapeutics company developing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a novel intratumoral radiation treatment that delivers radium-224 sources directly into solid tumors. The radium-224 decays into short-lived alpha-emitting daughters that disperse several millimeters throughout the tumor, emitting high-energy alpha particles that destroy cancer cells while sparing surrounding healthy tissue. The technology was originally developed in 2003 at Tel Aviv University by co-founders Prof. Itzhak Kelson and Prof. Yona Keisari, and Alpha Tau was incorporated in 2016. The company is advancing Alpha DaRT across multiple solid tumor indications including cutaneous squamous cell carcinoma, head and neck cancer, pancreatic cancer, glioblastoma, and prostate cancer, with five concurrent U.S. clinical trials (ReSTART, IMPACT, REGAIN, prostate, immunocompromised cSCC) and studies underway in Israel, Japan, France, Italy, and Canada.

Alpha Tau generates revenue through supply agreements and milestone payments rather than direct sales: it supplies Alpha DaRT to partner Tolmar International at 60% of net sales for U.S. urology commercialization under a 20-year exclusive arrangement, and to HekaBio K.K. for Japan head and neck cancer under a channel partnership following Japan's February 2026 PMDA Shonin approval. The company also receives up to $161.5M in clinical, regulatory, and commercial milestone payments from Tolmar, including $96.5M development/regulatory and $65M commercial milestones. As of March 2026, the company is pre-revenue with a Q1 2026 net loss of $22.9M and $80.2M in cash and equivalents; manufacturing is conducted at the Jerusalem facility and Lawrence, MA Thorium-228 generator site, with commercial-scale capacity being established in Hudson, NH.

The company is publicly listed on NASDAQ as DRTS following a March 2022 SPAC merger with Healthcare Capital Corp. (~$90M gross proceeds), and has since raised a $36.9M strategic investment from Oramed Pharmaceuticals (April 2025) and a $35M Tolmar investment (June 2026). The leadership team includes CEO Uzi Sofer, CFO Raphi Levy, and CMO Robert Den. Regulatory assets include FDA Breakthrough Device Designations for skin cancer and recurrent glioblastoma, FDA TAP Pilot acceptance, and the first Japan PMDA approval obtained outside Israel.

Name

Alpha Tau Medical

Legal name

Alpha Tau Medical Ltd.

Website

https://alphatau.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Alpha Tau Medical is an Israel-based clinical-stage oncology therapeutics company developing Alpha DaRT, an intratumoral radium-224 radiation therapy for solid tumors. It commercializes through Tolmar in U.S. urology and HekaBio in Japan, targeting multiple cancer indications including skin, head and neck, pancreatic, glioblastoma, and prostate cancers.

Ownership category

akta.pro rank

Product category

Intratumoral Radiotherapy / Cancer Treatment Devices

NAICS

Irradiation Apparatus Manufacturing (334517)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Radiation Oncology (HLAKAFAC), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)

Keywords

• Intratumoral radiation therapy
• Alpha emitter cancer treatment
• Solid tumor radiotherapy
• Radium-224 cancer device
• Diffusing alpha-emitter therapy

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Alpha DaRT Treatment Sales: Pre-revenue clinical stage company. Anticipates commercial revenue from Alpha DaRT treatments upon regulatory approvals. Japan approval obtained for head and neck cancer. U.S. pivotal trial (ReSTART) ongoing for cutaneous squamous cell carcinoma.
2. Supply/Sales to Partners: Alpha Tau manufactures and supplies Alpha DaRT to Tolmar at 60% of onward net sales price for U.S. prostate cancer commercialization. Similar supply arrangement expected with HekaBio for Japan market.
3. Milestone Payments: Up to $161.5M in clinical, regulatory, and commercial milestone payments from Tolmar, including $96.5M in development/regulatory milestones and $65M in commercial milestones for prostate cancer indication.
4. Equity Investment: $20M equity infusion at $11.99 per share from Tolmar, representing 25% premium to 30-day VWAP.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Alpha Tau Medical develops and manufactures Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), an intratumoral cancer treatment that delivers radium-224 impregnated sources directly into solid tumors. When radium-224 decays, short-lived alpha-emitting daughters disperse several millimeters and release high-energy alpha particles that destroy tumor cells while sparing surrounding healthy tissue. The treatment is designed as a one-time, minimally invasive procedure applicable across multiple solid tumor types.

Product overview

Alpha Tau Medical is a clinical-stage oncology therapeutics company developing a single core technology platform: Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Alpha DaRT is an intratumoral radiotherapeutic implant that delivers alpha-radiation directly into solid tumors using radium-224 sources. The company is advancing Alpha DaRT across multiple cancer indications including skin cancer (cutaneous squamous cell carcinoma), head and neck cancer, pancreatic cancer, glioblastoma (GBM), prostate cancer, breast cancer, lung cancer, liver cancer, and oral cavity cancer through various clinical trials (ReSTART, IMPACT, REGAIN, ACAPELLA, and others). The company was founded in 2016, went public via SPAC merger in March 2022 (NASDAQ: DRTS), and received its first regulatory approval outside Israel when Japan's PMDA approved Alpha DaRT for head and neck cancer in February 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) Alpha DaRT is an intratumoral alpha-radiation cancer therapy that delivers radium-224 impregnated sources directly into solid tumors. The sources release short-lived alpha-emitting daughters that disperse several millimeters into the tumor and emit high-energy alpha particles that destroy tumor cells while sparing surrounding healthy tissue. Designed as a one-time, minimally invasive procedure, Alpha DaRT is being advanced across multiple solid tumor indications including skin cancer, head and neck cancer, pancreatic cancer, glioblastoma, and prostate cancer.

Quantifiable outcome

• 100% local disease control in recurrent glioblastoma REGAIN trial (3 patients)
• +5 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core/flagship, minor and core.

• Tolmar International Ltd.core/flagshipStrategic or Co-development Partner · 3 June 2026Strategic collaboration to develop and commercialize Alpha DaRT for prostate cancer in the United States. Tolmar secures 20-year exclusive commercialization rights for urological cancers (prostate cancer, option for bladder cancer). Terms include $15M U.S. manufacturing investment, $20M equity infusion at $11.99/share (25% premium), and up to $161.5M in development/regulatory milestones ($96.5M) and commercial milestones ($65M). Alpha Tau leads clinical development and manufacturing, supplies at 60% of net sales. Alpha Tau retains all rights outside urological cancers in U.S. and all global rights.
• University of Verona Pancreas InstituteminorStrategic or Co-development Partner · 7 May 2026Clinical feasibility and safety study (Protocol CTP-PANC-03) for Alpha DaRT pancreatic cancer treatment. First Alpha DaRT protocol worldwide to permit both EUS-guided and percutaneous delivery methods. Part of global clinical expansion strategy.
• HekaBio K.K.coreChannel Partner/ Reseller/ Distributor · 24 February 2026Japan commercialization partner for Alpha DaRT head and neck cancer following PMDA Shonin marketing approval - first regulatory approval outside Israel. HekaBio preparing commercial launch and conducting post-market surveillance study of 66 patients across 5 Japanese clinical centers.
• Mayo Clinic, McGill University, Emory University, MD Anderson Cancer CenterminorStrategic or Co-development Partner · 29 January 2026Preclinical research partnerships exploring different combinations with immunotherapy for future Alpha DaRT applications. Part of strategic pillar exploring systemic benefits of Alpha DaRT for metastatic tumors.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Novartis (Pluvicto/Lutathera): Novartis is the leading commercial-stage player in therapeutic radiopharmaceuticals with Pluvicto (lutetium-177 PSMA-617 for prostate cancer) and Lutathera — directly comparable to Alpha DaRT as a targeted radioligand/radio-emitter therapy for solid tumors with similar treatment-center delivery model.
• Bayer (Xofigo/radium-223): Bayer markets Xofigo (radium-223 dichloride), the only approved radium-based therapeutic for cancer — directly comparable to Alpha DaRT as a targeted radium-emitter therapy with overlapping regulatory precedent and oncology channel relationships.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with a portfolio of diagnostic and therapeutic radioisotope products, advancing into alpha-emitter and theranostic solid tumor indications — directly comparable in manufacturing, regulatory, and commercial infrastructure.
• Telix Pharmaceuticals: Telix develops and commercializes diagnostic and therapeutic radiopharmaceuticals across oncology indications including prostate cancer and GBM — directly comparable to Alpha DaRT in solid tumor applications and regulatory pathway.
• POINT Biopharma (acquired by Eli Lilly): POINT was a clinical-to-commercial radiopharmaceutical company developing targeted radioligand therapies for cancer — the most direct U.S. precedent for Alpha DaRT's radioligand approach, now within Lilly's oncology portfolio.
• OncoSil Medical: OncoSil is a clinical-to-commercial medical device company developing intratumoral brachytherapy for solid tumors, including pancreatic cancer — closely comparable intratumoral implantation modality, treatment-center delivery, and cancer indication overlap.

Emerging players

• Clarity Pharmaceuticals: Clarity is a clinical-stage radiopharmaceutical company developing next-generation targeted radiopharmaceuticals for oncology — directly comparable emerging peer pursuing theranostic solid tumor approaches with overlapping clinical read-out timing.
• Perspective Therapeutics: Perspective is a clinical-stage radiopharmaceutical company developing alpha- and beta-emitting therapies for solid tumors including prostate cancer — emerging peer with overlapping radio-emitter solid tumor franchise and similar partnership-driven commercialization model.

Broad incumbents

• ITM Isotope Technologies Munich: ITM is a specialized radiopharmaceutical manufacturer and developer producing therapeutic and diagnostic medical radioisotopes — directly comparable in radioisotope production infrastructure required to scale Alpha DaRT's radium-224 supply chain.
• Elekta: Elekta is a global vendor of radiation therapy and radiosurgery equipment and software to oncology centers — comparable as a radiation oncology delivery platform competing for the same hospital-based treatment slot and capital budget that Alpha DaRT will require.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alphataumedical
• YouTubeyoutube.com/channel/UCMmWvVwo1iEaQbncaIrK1PQ
• Facebookfacebook.com/AlphaTauMedical
• LinkedInlinkedin.com/company/alphataumedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alpha Tau Medical